Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: anti-infectives - BlueWillow Biologics

Drug Profile

Research programme: anti-infectives - BlueWillow Biologics

Alternative Names: NB-005; NB-201; NB-401; NB-402; Topical nanoemulsions for bacterial infections - BlueWillow Biologics; Vaginitis nanoemulsion (NB Prototype-1); Vaginitis nanoemulsion (NB Prototype-2)

Latest Information Update: 09 May 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator NanoBio Corporation
  • Developer BlueWillow Biologics; NanoBio Corporation; University of Michigan Medical School
  • Class
  • Mechanism of Action Virus internalisation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • No development reported Burn infections; Cystic fibrosis-associated respiratory tract infections; Herpes simplex virus infections; Influenza virus infections; Methicillin-resistant Staphylococcus aureus infections; Vaginitis; Wound infections
  • Discontinued Herpes zoster

Most Recent Events

  • 07 May 2018 NanoBio Corporation is now called BlueWillow Biologics
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Burn-infections in USA (Topical, Lotion)
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Cystic-fibrosis-associated-respiratory-tract-infections in USA (Inhalation)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top